Its potential efficacy in regulating immune responses, combined with its structural stability when bound to JAK2, makes it an attractive therapeutic option for viral infections such as MERS-CoV, hepatitis B, and influenza A. Future studies should focus on the in vivo evaluation of the antiviral activity of this compound to validate its clinical potential. The gene discussed is JAK2; the disease is hepatitis B virus infection.